U.S. Ties Federal Funding to Verified DNA Screening to Counter AI Biosecurity Risks

The United States government has officially tied federal life-sciences funding to verified biosecurity screening, closing a major loophole in the synthetic DNA supply chain. The new mandate requires laboratories to purchase genetic materials exclusively from certified suppliers. The policy aims to intercept engineered biological threats before they can be physically manufactured.[1][2]

The National Policy for Nucleic Acid Synthesis Screening, issued via memorandum NSTM-6 on November 5, 2026, replaces a previous framework that relied on voluntary self-attestation. Signed by National Security Advisor Marco Rubio and Office of Science and Technology Policy Director Michael Kratsios, the directive establishes a strict procurement gate for any institution receiving federal grants.[1][2][3]

Under the new rules, the National Institute of Standards and Technology (NIST) will verify the screening tools used by commercial DNA providers. "For too long, American biotechnology leaders and other responsible innovators have had to compete against firms that bypass biosecurity safeguards for economic gain," the policy document states.[1]

The administration explicitly framed the policy as a defense against the rapid advancement of artificial intelligence in the biological sciences. The document repeatedly cites the risk of "super intelligence" uplift, warning that advanced models could help malicious actors design novel pathogens or evade traditional detection methods.[1][2]

Targeting the AI Threat

To counter these emerging capabilities, the policy directs NIST to research and validate AI-assisted screening approaches. These next-generation tools will be integrated into the government's initial standards to the greatest extent feasible, shifting the industry from static, list-based checks to dynamic, risk-based evaluations.[1][2]

The focus on advanced AI misuse extends beyond procurement rules. On the same day the policy was released, Attorney General Todd Blanche announced the formation of a Department of Justice Super Intelligence Task Force. Led by Stanley Woodward and Stephen Weiss, the group will coordinate criminal investigations into the misuse of advanced models by foreign actors and criminal networks.[2]

By synchronizing the White House procurement mandate with the DOJ's enforcement initiative, federal officials are attempting to secure both the digital design phase and the physical manufacturing phase of synthetic biology. "Through this Policy, the Administration is building a dynamic biosecurity defense centered on strong controls over the materials that enable synthetic biology misuse," the memorandum notes.[1]

The policy also addresses a critical vulnerability that biosecurity experts have warned about for years: the proliferation of benchtop DNA synthesizers. These localized "DNA printers" allow laboratories to manufacture genetic material on-site, bypassing the centralized screening processes used by major mail-order synthesis companies.[2][3]

Securing Benchtop Synthesizers

Under the new directive, benchtop equipment will be subjected to rigorous operational controls. A synthesizer may only initiate a print run if it receives a valid, unexpired authorization from a NIST-verified screening system. This ensures that sequences are checked against pathogen databases even when printed locally.[1][2]

Manufacturers of benchtop devices must also implement tamper-resistant record-keeping systems. These logs must be synchronized with verified screeners at least quarterly, and limited offline operation will only be permitted in specific modes approved by NIST. The requirements effectively tether decentralized hardware to centralized security standards.[2]

The technical parameters of sequence screening are also undergoing a significant revision. Previously, the International Gene Synthesis Consortium's harmonized protocol required providers to screen orders of 200 base pairs or longer. The new federal policy drastically reduces this threshold, targeting orders of 50 or more nucleotides.[1][3]

AI

This shorter window is designed to catch fragmented sequences of concern. Malicious actors could theoretically order small, innocuous-looking oligonucleotides from multiple suppliers and assemble them into a dangerous pathogen later. By screening at the 50-nucleotide level, providers can better detect these distributed evasion attempts.[3]

Verifying the Customer

Sequence screening is only one half of the biosecurity equation; the policy also mandates rigorous "Know Your Customer" (KYC) protocols. If an order contains a sequence of concern, the customer's legitimacy must be verified at two distinct points: by the supplier when establishing the commercial relationship, and by the verified screener at the individual order level.[1][3]

This dual-verification system ensures that sensitive genetic materials are only shipped to legitimate research institutions. The verified screener is responsible for assessing the order, issuing a formal screening determination, and reporting any flagged requests to appropriate federal authorities, including the FBI.[1][2]

The supplier and the screener share the responsibility for maintaining these records. The policy requires that all screening determinations and KYC verifications be retained for a minimum of eight years, providing a durable audit trail for federal investigators in the event of a biosecurity incident.[2]

The implementation timeline is aggressive, measured in days from the memorandum's release. NIST is required to issue the foundational screening and benchtop standards by Day 90. By Day 100, the agency will begin officially verifying the screening tools submitted by commercial providers.[1][2]

A Strict Compliance Timeline

The Department of Health and Human Services (HHS) will publish its first official list of "Adherent Suppliers" by Day 160. These are the certified companies that have successfully integrated NIST-verified tools and demonstrated compliance with the new KYC and reporting mandates.[2]

For federally funded laboratories, the procurement window closes shortly after. Customers must source all synthetic nucleic acids exclusively through Adherent Suppliers by Day 250. The deadline for purchasing compliant benchtop synthesis equipment is set for Day 340.[1][2]

The enforcement mechanisms attached to these deadlines are severe. The memorandum declares that compliance is material to the government's payment decisions under the False Claims Act. Institutions that violate the procurement rules face immediate revocation of their ongoing federal funding.[2]

Beyond immediate financial penalties, violators can be deemed ineligible for federal grants for up to five years. By leveraging the massive purchasing power of the National Institutes of Health and other federal agencies, the White House is effectively forcing the entire domestic market to adopt the new standards.[2][3]

Shifting the Global Market

While the policy directly binds only federally funded purchasers, its market impact will likely be universal. Major DNA synthesis providers cannot afford to run separate, less-secure production lines for private clients, meaning the NIST-verified standards will become the de facto baseline for the entire U.S. bioeconomy.[3]

The U.S. move highlights a growing disparity in global biosecurity capabilities. While American and European regulators are tightening controls over synthetic DNA, experts warn that regions across the Global South currently lack the infrastructure to implement comprehensive sequence screening, creating potential vulnerabilities in the international supply chain.[3]

Until the new framework is fully operational, the existing 2023 HHS screening guidance remains in effect. Laboratories and procurement officers are currently auditing their supply chains to ensure their preferred vendors are preparing for the upcoming NIST certification process.[2][3]

The success of the initiative now depends on the technical execution over the next three months. The biosecurity community is waiting to see exactly how NIST will define the operational standards for AI-assisted screening when the agency releases its initial guidelines on Day 90.[1][2]